Horizon Therapeutics PLC (NASDAQ:HZNP) – Equities researchers at Piper Sandler lowered their Q1 2020 EPS estimates for shares of Horizon Therapeutics in a report issued on Tuesday, February 11th. Piper Sandler analyst D. Amsellem now expects that the biopharmaceutical company will earn $0.34 per share for the quarter, down from their prior estimate of $0.36. Piper Sandler also issued estimates for Horizon Therapeutics’ Q2 2020 earnings at $0.46 EPS, Q3 2020 earnings at $0.55 EPS, Q4 2020 earnings at $0.64 EPS, FY2020 earnings at $1.99 EPS, Q1 2021 earnings at $0.58 EPS, Q2 2021 earnings at $0.71 EPS, Q3 2021 earnings at $0.78 EPS, Q4 2021 earnings at $0.84 EPS, FY2021 earnings at $2.91 EPS, FY2022 earnings at $3.59 EPS and FY2023 earnings at $3.89 EPS.
HZNP has been the topic of several other reports. BMO Capital Markets raised their price target on shares of Horizon Therapeutics from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Stifel Nicolaus raised their price target on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Jefferies Financial Group raised their price target on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. BidaskClub downgraded shares of Horizon Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 31st. Finally, Morgan Stanley raised their price target on shares of Horizon Therapeutics from $32.00 to $38.00 and gave the stock an “overweight” rating in a research note on Monday, December 16th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Horizon Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $37.57.
In other news, EVP Brian K. Beeler sold 9,969 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $32.51, for a total value of $324,092.19. Following the transaction, the executive vice president now directly owns 89,633 shares of the company’s stock, valued at approximately $2,913,968.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brian K. Beeler sold 6,716 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $35.00, for a total value of $235,060.00. Following the completion of the transaction, the executive vice president now directly owns 77,917 shares in the company, valued at $2,727,095. The disclosure for this sale can be found here. Insiders have sold a total of 114,413 shares of company stock worth $4,039,099 over the last ninety days. Company insiders own 4.10% of the company’s stock.
Several large investors have recently made changes to their positions in HZNP. IFP Advisors Inc increased its position in shares of Horizon Therapeutics by 163.0% during the fourth quarter. IFP Advisors Inc now owns 1,086 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 673 shares in the last quarter. Quadrant Capital Group LLC acquired a new position in Horizon Therapeutics during the third quarter worth about $66,000. Contravisory Investment Management Inc. acquired a new position in Horizon Therapeutics during the fourth quarter worth about $171,000. M&T Bank Corp acquired a new position in Horizon Therapeutics during the fourth quarter worth about $215,000. Finally, Banque Cantonale Vaudoise acquired a new position in Horizon Therapeutics during the fourth quarter worth about $228,000. 88.51% of the stock is currently owned by institutional investors.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Read More: How to calculate compound interest
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.